Serum IL-9 levels and sublingual immunotherapy: Preliminary report

Giorgio Ciprandi, M. De Amici, G. L. Marseglia

Research output: Contribution to journalArticlepeer-review


Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p

Original languageEnglish
Pages (from-to)295-297
Number of pages3
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number2
Publication statusPublished - Apr 2011


  • Allergic rhinitis
  • Pollen allergy
  • Serum IL-9
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research


Dive into the research topics of 'Serum IL-9 levels and sublingual immunotherapy: Preliminary report'. Together they form a unique fingerprint.

Cite this